Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Agenus from a "buy" to a "hold" and Weiss Ratings reiterated a "sell (e+)", leaving the consensus analyst rating at "Hold" with an average price target of $14.50.
• Agenus reported quarterly results that beat estimates—$0.56 EPS versus a ($1.27) consensus and $34.2M revenue versus $28.1M—but still showed a negative net margin (‑2.67%) and negative ROE (‑7.65%), with sell-side analysts forecasting a steeply negative EPS (‑12.55) for the current fiscal year.
• The stock trades at about $3.39 with a $130.2M market cap, a 52‑week range of $1.38–$7.34 and a beta of 1.57, and institutions own roughly 61.46% of the shares.

Agenus (NASDAQ:AGEN - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Agenus in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $14.50.

Agenus Stock Performance

Agenus stock opened at $3.39 on Friday. The stock has a market cap of $130.17 million, a PE ratio of -7.37 and a beta of 1.57. The stock has a fifty day moving average of $3.21 and a 200 day moving average of $3.73. Agenus has a one year low of $1.38 and a one year high of $7.34.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.83. The firm had revenue of $34.20 million during the quarter, compared to the consensus estimate of $28.10 million. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. As a group, sell-side analysts predict that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

Hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC purchased a new position in Agenus during the fourth quarter valued at approximately $31,000. R Squared Ltd purchased a new position in shares of Agenus in the 4th quarter valued at $41,000. Redwood Family Wealth LLC purchased a new position in shares of Agenus in the 4th quarter valued at $44,000. Traynor Capital Management Inc. bought a new position in shares of Agenus in the 3rd quarter worth $50,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Agenus during the 4th quarter worth $54,000. Hedge funds and other institutional investors own 61.46% of the company's stock.

Agenus Company Profile

Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.